9470127|t|PET and the investigation of dementia in the parkinsonian patient.
9470127|a|Parkinsonism and dementia are present in a number of neurodegenerative conditions. They may be a manifestation of isolated brain stem (Parkinson's disease) or diffuse Lewy body disease (DLBD), or be secondary to combined Lewy body and Alzheimer's disease (AD) pathologies. Positron emission tomography (PET) studies show a resting pattern of fronto-temporo-parietal hypometabolism in both, AD and in parkinsonism-dementia (PD-dementia) patients, even when only isolated brain stem Lewy body disease is found at pathology. We have studied three patients fulfilling clinical criteria for diagnosis of DLBD. Their 18F-fluorodeoxyglucose (FDG) PET results showed an AD pattern of fronto-temporo-parietal hypometabolism, though these patients had only mild cognitive dysfunction. Parkinsonism associated with apraxia is observed in corticobasal degeneration (CBD) while impairment of frontal functions, such as planning and sorting, is seen in patients with progressive supranuclear palsy (PSP). PET studies in CBD patients have shown an asymmetric hypometabolism of cortex and thalamus contralateral to the affected limbs, while in PSP patients there is a global metabolic reduction most pronounced in frontal areas and the basal ganglia. These results suggest that metabolic PET studies can help to distinguish PD-dementia, PSP and CBD, but are unable to distinguish PD-dementia from AD. Further studies with post-mortem confirmation are required to establish if DLBD is associated with a distinctive pattern of resting hypometabolism.
9470127	29	37	dementia	Disease	MESH:D003704
9470127	45	57	parkinsonian	Disease	MESH:D010300
9470127	58	65	patient	Species	9606
9470127	67	79	Parkinsonism	Disease	MESH:D010302
9470127	84	92	dementia	Disease	MESH:D003704
9470127	120	148	neurodegenerative conditions	Disease	MESH:D019636
9470127	202	221	Parkinson's disease	Disease	MESH:D010300
9470127	226	251	diffuse Lewy body disease	Disease	MESH:D020961
9470127	253	257	DLBD	Disease	MESH:D020961
9470127	288	297	Lewy body	Disease	MESH:D020961
9470127	302	321	Alzheimer's disease	Disease	MESH:D000544
9470127	323	325	AD	Disease	MESH:D000544
9470127	433	447	hypometabolism	Disease	
9470127	457	459	AD	Disease	MESH:D000544
9470127	467	488	parkinsonism-dementia	Disease	MESH:C537240
9470127	490	501	PD-dementia	Disease	MESH:D010300
9470127	503	511	patients	Species	9606
9470127	548	565	Lewy body disease	Disease	MESH:D020961
9470127	611	619	patients	Species	9606
9470127	666	670	DLBD	Disease	MESH:D020961
9470127	678	700	18F-fluorodeoxyglucose	Chemical	MESH:D019788
9470127	702	705	FDG	Chemical	MESH:D019788
9470127	729	731	AD	Disease	MESH:D000544
9470127	767	781	hypometabolism	Disease	
9470127	796	804	patients	Species	9606
9470127	819	840	cognitive dysfunction	Disease	MESH:D003072
9470127	842	854	Parkinsonism	Disease	MESH:D010302
9470127	871	878	apraxia	Disease	MESH:D001072
9470127	894	919	corticobasal degeneration	Disease	MESH:D000088282
9470127	921	924	CBD	Disease	MESH:D000088282
9470127	932	963	impairment of frontal functions	Disease	MESH:D003072
9470127	1006	1014	patients	Species	9606
9470127	1020	1050	progressive supranuclear palsy	Disease	MESH:D013494
9470127	1052	1055	PSP	Disease	MESH:D013494
9470127	1073	1076	CBD	Disease	MESH:D000088282
9470127	1077	1085	patients	Species	9606
9470127	1111	1125	hypometabolism	Disease	
9470127	1195	1198	PSP	Disease	MESH:D013494
9470127	1199	1207	patients	Species	9606
9470127	1375	1386	PD-dementia	Disease	MESH:D010300
9470127	1388	1391	PSP	Disease	MESH:D013494
9470127	1396	1399	CBD	Disease	MESH:D000088282
9470127	1431	1442	PD-dementia	Disease	MESH:D010300
9470127	1448	1450	AD	Disease	MESH:D000544
9470127	1527	1531	DLBD	Disease	MESH:D020961
9470127	1576	1598	resting hypometabolism	Disease	MESH:D014202

